.

follow-on-google-news

With a market capitalization of  ₹9,823 crore, Medplus Health Services Ltd. shares surged 20% on Friday to reach an intraday high of  ₹ 827.70 apiece from the previous close price of  ₹687.65. The company’s net profit for the March quarter doubled by 136 percent, and revenue for the quarter rose 30 percent over the last quarter.

At 13:00 am, the stock was trading at  ₹821.45 on the BSE, up 19.04 percent from its previous close. One of the probable reasons for the stock to hit a high price is the company’s recent announcement of strong Q4 FY 22-23 earnings.

Medplus health services Ltd. is one of India’s leading healthcare companies, engaged in the manufacturing of private-label pharmaceutical, wellness, and FMCG products, wholesale and retail sales, import, distribution, and pathology diagnostic laboratory testing. The company has 2,165 stores in 242 cities distributed across Tamil Nadu, Andhra Pradesh, Telangana, Karnataka, Odisha, West Bengal, and Maharashtra.

Note: If you want to learn Candlesticks and Chart Trading from Scratch, here’s the best book available on Amazon! Get the book now!

Having a quick walkthrough of the financials reported by the company, In Q4FY23, PAT jumped 136% to ₹26 crores as against ₹11 crores in Q4FY22. Revenue stood at ₹1,252 crore, up by 30% from ₹965 crore in Q4 FY22.

On a YoY comparison of the metrics, the revenues significantly improved from ₹3,779 crores during FY 21-22 to ₹4,558 crores in FY 22-23. The PAT numbers have shifted downwards within the timeframe mentioned, from ₹ 95 crores to 50 crores. 

In the past three months, the stock has jumped around 26.41 percent, ranging from  ₹659.25 to the current price levels. 

According to the latest data pertaining to the shareholding pattern, promoters of the company hold a 40.43 percent stake, and domestic institutional investors (DIIs) hold a 28.16 percent stake in the company for FY 22-23.

Written by Omkar C

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.